Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,740.50GBp
11:36am EDT
Change (% chg)

-0.50 (-0.03%)
Prev Close
1,741.00
Open
1,745.50
Day's High
1,751.50
Day's Low
1,720.50
Volume
544,232
Avg. Vol
511,350
52-wk High
2,089.00
52-wk Low
1,368.00

Latest Key Developments (Source: Significant Developments)

Hikma Appoints Cynthia Schwalm As Director
Tuesday, 12 Mar 2019 03:02am EDT 

March 12 (Reuters) - Hikma Pharmaceuticals PLC ::DIRECTORATE CHANGE.HIKMA BOARD APPOINTS CYNTHIA SCHWALM AS DIRECTOR.APPOINTMENT OF CYNTHIA SCHWALM AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR EFFECTIVE 1 JUNE 2019.  Full Article

Hikma Establishes Partnership With Melinta In MENA Region
Thursday, 28 Feb 2019 04:00am EST 

Feb 28 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - HIKMA ESTABLISHES PARTNERSHIP WITH MELINTA IN MENA.HIKMA PHARMACEUTICALS PLC - HAS RIGHT OF FIRST NEGOTIATION FOR ALL OTHER PRODUCTS IN MELINTA'S PORTFOLIO AND PIPELINE IN MENA REGION.HIKMA- EXCLUSIVE LICENSE, SUPPLY, DISTRIBUTION AGREEMENT WITH MELINTA FORMELINTA'S INTRAVENOUS, ORAL FORMULATIONS OF BAXDELA ACROSS ALL MENA MARKETS.  Full Article

Hikma Pharmaceutical USA Launches Mitomycin For Injection
Tuesday, 29 Jan 2019 04:00am EST 

Jan 29 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - HIKMA LAUNCHES MITOMYCIN FOR INJECTION.HIKMA PHARMACEUTICALS PLC - HIKMA PHARMACEUTICALS USA INC LAUNCHED MITOMYCIN FOR INJECTION, USP, 20MG AND 40MG.  Full Article

Hikma Announces Agreement With Sciecure Pharma
Thursday, 3 Jan 2019 04:00am EST 

Jan 3 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ANNOUNCES AGREEMENT WITH SCIECURE PHARMA.SCIECURE EXPECTS TO FILE THIS PRODUCT FOR APPROVAL WITH US FOOD AND DRUG ADMINISTRATION IN EARLY 2019.AGREEMENT PROVIDES CO EXCLUSIVE RIGHTS TO SELL ONE OF SCIECURE'S NICHE INJECTABLE ANTI-VIRAL MEDICINES ACROSS US FOR A MINIMUM OF EIGHT YEARS.DEAL HAS OPTION TO EXTEND PARTNERSHIP WITH SCIECURE FOR AN ADDITIONAL TWO YEARS.  Full Article

Joint Venture Between Gordon Brothers, New Mill Capital Acquired Three Buildings From Hikma Pharmaceuticals
Wednesday, 2 Jan 2019 04:39pm EST 

Jan 2 (Reuters) - Hikma Pharmaceuticals PLC ::GORDON BROTHERS - JOINT VENTURE BETWEEN GORDON BROTHERS, NEW MILL CAPITAL ACQUIRED THREE BUILDINGS FROM HIKMA PHARMACEUTICALS IN EATONTOWN, NJ.  Full Article

Hikma Announces Agreement With Vectura
Thursday, 8 Nov 2018 02:01am EST 

Nov 8 (Reuters) - Hikma Pharmaceuticals Plc ::HIKMA ANNOUNCES AGREEMENT WITH VECTURA.UPON SIGNING, HIKMA WILL MAKE AN UPFRONT PAYMENT OF $15 MILLION TO VECTURA.VECTURA WILL BE RESPONSIBLE FOR, AND FUND, INITIAL DEVICE AND FORMULATION DEVELOPMENT.DEAL FOR GLOBAL DEVELOPMENT AND COMMERCIALISATION OF GENERIC VERSIONS OF GSK'S ELLIPTA PORTFOLIO.UPON TRANSFER OF 1ST PRODUCT TO CO'S MANUFACTURING FACILITY, WILL MAKE $5 MILLION MILESTONE PAYMENT TO VECTURA.THEREAFTER, HIKMA WILL MAKE MILESTONE PAYMENTS OF UP TO $75 MILLION AT VARIOUS STAGES OF DEVELOPMENT.VECTURA WILL CONTRIBUTE UP TO $70 MILLION TOWARDS HIKMA'S DEVELOPMENT ACTIVITIES FOR PORTFOLIO.HIKMA PHARMACEUTICALS - VECTURA'S CONTRIBUTION TO BE MADE THROUGH REDUCED PROFIT SHARE MECHANISM FOLLOWING COMMERCIAL LAUNCH OF FIRST PRODUCT.  Full Article

Hikma Pharmaceuticals Raises Guidance For Injectables, Generics Businesses For Full Year
Wednesday, 15 Aug 2018 02:00am EDT 

Aug 15 (Reuters) - Hikma Pharmaceuticals PLC ::H1 OPERATING PROFIT 174 MILLION USD VERSUS 113 MILLION USD YEAR AGO.H1 REVENUE 989 MILLION USD VERSUS 895 MILLION USD YEAR AGO.INTERIM DIVIDEND 0.12 USDPER SHARE.GUIDANCE RAISED FOR INJECTABLES AND GENERICS BUSINESSES AND REITERATED FOR BRANDED BUSINESS.RAISE GUIDANCE FOR BOTH OUR INJECTABLES AND GENERICS BUSINESSES FOR FULL YEAR.NOW EXPECT FULL YEAR INJECTABLES REVENUE TO BE IN RANGE OF $775 MILLION TO $825 MILLION.EXPECT GENERICS FULL YEAR REVENUE TO BE IN RANGE OF $600 MILLION TO $650 MILLION.EXPECT BRANDED REVENUES TO BE HIGHER IN SECOND HALF OF YEAR.EXPECT FULL YEAR BRANDED REVENUE GROWTH IN CONSTANT CURRENCY TO BE IN MID-SINGLE DIGITS.DON'T EXPECT SAME DEMAND FOR SOME OF OUR INJECTABLE PRODUCTS TO CONTINUE INTO 2019.NOT CLEAR HOW LONG INJECTABLE OPIOIDS SHORTAGES WILL PERSIST; DON'T EXPECT TO SEE SAME LEVEL OF DEMAND CONTINUE INTO 2019.MENA INJECTABLES REVENUE WAS $51 MILLION IN H1 2018, UP 46%.IN H1 2018, GLOBAL INJECTABLES REVENUE INCREASED BY 14% TO $414 MILLION.CONTINUE TO EXPECT GROUP CAPITAL EXPENDITURE IN RANGE OF $120 MILLION TO $140 MILLION IN 2018.  Full Article

Acorda Updates On Litigation With Mylan, Teva, West-Ward Pharma & Hikma
Friday, 3 Aug 2018 06:05am EDT 

Aug 3 (Reuters) - Acorda Therapeutics Inc ::ACORDA THERAPEUTICS - UPDATES ON LITIGATION WITH MYLAN, TEVA, WEST-WARD PHARMACEUTICALS INTERNATIONAL & HIKMA PHARMACEUTICALS USA.ACORDA THERAPEUTICS - TERMS OF SETTLEMENT AGREEMENT WITH MYLAN AND INTERIM AGREEMENTS WITH TEVA AND HIKMA ARE OTHERWISE CONFIDENTIAL.ACORDA THERAPEUTICS - MYLAN WILL BE PERMITTED TO MARKET ITS GENERIC VERSION OF AMPYRA IN U.S. SOMETIME IN 2025/EARLIER AS PER A CONDITIONED SETTLEMENT WITH CO.ACORDA THERAPEUTICS - SIGNED INTERIM AGREEMENT WITH TEVA CONCERNING PATENT LITIGATION RELATING TO AMPYRA THAT ADDRESSES PERIOD OF TIME UNTIL AUG 31.ACORDA THERAPEUTICS SAYS ALSO SIGNED INTERIM AGREEMENT WITH HIKMA CONCERNING THEIR PATENT LITIGATION RELATING TO AMPYRA - SEC FILING.  Full Article

Hikma Pharmaceuticals Says U.S. Business Releases Hydromorphone To Hospital Customers
Wednesday, 18 Jul 2018 07:00am EDT 

July 18 (Reuters) - Hikma Pharmaceuticals PLC ::CO'S US BUSINESS RELEASING "SIGNIFICANT QUANTITIES" OF HYDROMORPHONE TO US HOSPITAL CUSTOMERS TO HELP WITH SHORTAGE OF INJECTABLE OPIOIDS.RELEASED MORE THAN 5 MILLION HYDROMORPHONE 2ML VIALS TO US HOSPITALS IN JUNE, EXPECTS TO RELEASE ANOTHER THREE MILLION VIALS IN JULY.  Full Article

Hikma Enters Licensing Partnership With Perrigo
Monday, 9 Jul 2018 04:00am EDT 

July 9 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA ENTERS LICENSING PARTNERSHIP WITH PERRIGO.SIGNED LICENSING AND DISTRIBUTION AGREEMENT WITH OMEGA PHARMA TRADING NV.HIKMA HAS EXCLUSIVE RIGHT TO LICENSE AND DISTRIBUTE MORE THAN 30 CONSUMER HEALTHCARE PRODUCTS IN ALL ITS MENA MARKETS.IN ADDITION, HIKMA HAS RIGHT OF FIRST REFUSAL TO FULL RANGE OF PERRIGO'S OTC MEDICINES IN MENA REGION.  Full Article

UPDATE 1-Hikma backs annual outlook on demand for its new drugs

May 17 Hikma Pharmaceuticals Plc on Friday backed its forecast for the full year, boosted by higher demand for its new drugs and generic medicines.